{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combinations", "query": { "intervention": "Combinations" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1136, "total_pages": 114, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combinations&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-08T00:06:40.405Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03459222", "title": "An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "Relatlimab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "BMS-986205", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 229, "start_date": "2018-05-30", "completion_date": "2025-02-19", "has_results": true, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-09-08T00:06:40.405Z", "location_count": 5, "location_summary": "Duarte, California • Aurora, Colorado • Baltimore, Maryland + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Germantown", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03459222" }, { "nct_id": "NCT01262092", "title": "Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Opioid Dependence", "Opioid Withdrawal", "Opioid Detoxification" ], "interventions": [ { "name": "Buprenorphine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2010-10", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2013-06-21", "last_synced_at": "2026-09-08T00:06:40.405Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01262092" }, { "nct_id": "NCT02651584", "title": "Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Opioid Use Disorders" ], "interventions": [ { "name": "CAM2038 SC injection", "type": "DRUG" }, { "name": "SL BPN/NX tabs", "type": "DRUG" }, { "name": "placebo SC injections", "type": "DRUG" }, { "name": "SL placebo tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Braeburn Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 428, "start_date": "2015-12", "completion_date": "2016-11", "has_results": true, "last_update_posted_date": "2019-08-22", "last_synced_at": "2026-09-08T00:06:40.405Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Haleyville, Alabama • Hamilton, Alabama + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Haleyville", "state": "Alabama" }, { "city": "Hamilton", "state": "Alabama" }, { "city": "Lemon Grove", "state": "California" }, { "city": "Oceanside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02651584" }, { "nct_id": "NCT02915016", "title": "Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "DNA-HIV-PT123 vaccine", "type": "BIOLOGICAL" }, { "name": "Bivalent Subtype C gp120/MF59 vaccine", "type": "BIOLOGICAL" }, { "name": "Bivalent Subtype C gp120/AS01B vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 334, "start_date": "2016-12-07", "completion_date": "2020-02-12", "has_results": true, "last_update_posted_date": "2022-04-29", "last_synced_at": "2026-09-08T00:06:40.405Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Boston, Massachusetts • New York, New York + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02915016" }, { "nct_id": "NCT04723940", "title": "Or v IV Antibiotics for Infection", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Joint Infection" ], "interventions": [ { "name": "Bactrim", "type": "DRUG" }, { "name": "Cefadroxil", "type": "DRUG" }, { "name": "Doxycycline Hcl", "type": "DRUG" }, { "name": "Clindamycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rothman Institute Orthopaedics", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 308, "start_date": "2021-01-25", "completion_date": "2023-01-25", "has_results": false, "last_update_posted_date": "2021-01-26", "last_synced_at": "2026-09-08T00:06:40.405Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04723940" }, { "nct_id": "NCT06473779", "title": "Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Severe Asthma" ], "interventions": [ { "name": "Tezepelumab", "type": "COMBINATION_PRODUCT" }, { "name": "Budesonide/formoterol", "type": "COMBINATION_PRODUCT" }, { "name": "Albuterol/budesonide (AIRSUPRA®)", "type": "COMBINATION_PRODUCT" }, { "name": "Mannitol", "type": "COMBINATION_PRODUCT" }, { "name": "Salbutamol", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "12 Years to 80 Years" }, "enrollment_count": 326, "start_date": "2024-09-30", "completion_date": "2027-06-25", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-09-08T00:06:40.405Z", "location_count": 8, "location_summary": "Palmdale, California • Colorado Springs, Colorado • Miami, Florida + 5 more", "locations": [ { "city": "Palmdale", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06473779" }, { "nct_id": "NCT01336140", "title": "Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson" ], "interventions": [ { "name": "Aminophylline", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rush University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2011-06", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2023-01-26", "last_synced_at": "2026-09-08T00:06:40.405Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01336140" }, { "nct_id": "NCT03309696", "title": "Regulating Homeostatic Plasticity and the Physiological Response to rTMS", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Tinnitus" ], "interventions": [ { "name": "sham tDCS and sham rTMS", "type": "DEVICE" }, { "name": "sham tDCS and active rTMS", "type": "DEVICE" }, { "name": "active tDCS and active rTMS", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 10, "start_date": "2017-11-16", "completion_date": "2019-10-01", "has_results": true, "last_update_posted_date": "2020-11-17", "last_synced_at": "2026-09-08T00:06:40.405Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03309696" }, { "nct_id": "NCT06062420", "title": "A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms, Head and Neck" ], "interventions": [ { "name": "Dostarlimab", "type": "DRUG" }, { "name": "Belrestotug", "type": "DRUG" }, { "name": "Nelistotug", "type": "DRUG" }, { "name": "Remzistotug", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 316, "start_date": "2023-11-14", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-09-08T00:06:40.405Z", "location_count": 5, "location_summary": "New Haven, Connecticut • Iowa City, Iowa • St Louis, Missouri + 2 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT06062420" }, { "nct_id": "NCT02826343", "title": "New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Xenon129 MRI imaging", "type": "DRUG" }, { "name": "Gadolinium MRI", "type": "DRUG" }, { "name": "Advair (250mcg/50mcg) one puff twice a day", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 30, "start_date": "2016-05-01", "completion_date": "2018-06-15", "has_results": false, "last_update_posted_date": "2020-11-04", "last_synced_at": "2026-09-08T00:06:40.405Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02826343" } ] }